Lead Product(s) : ATH-063
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063
Details : ATH-063 is a first-in-class, oral, small molecule, genomic regulator acts both by suppressing pro-inflammatory responses and inducing direct mucosal healing, being developed for inflammatory bowel diseases, other autoimmune diseases and solid cancers.
Product Name : ATH-063
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2023
Lead Product(s) : ATH-063
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
